Diagnostic tests used in cancer detection, imaging and staging are quite expensive. Development of new cost effective biomarkers and point of care diagnostic kits will be our focus. Emphasis will be on non-invasive markers either radiological, biochemical or genetic for detection of pre-neoplastic conditions,markers of disease status and prognostic markers. The potential of synthetic biomarkers e.g. a nanoparticle that interacts with tumor proteins/ enzymes to release fragments that can be detected in the diagnosis of various tumors will be studied. New diagnostic tools to diagnose tumors such as thermography and the use of AI will also be explored.